Atul is a physician with over 18 years’ experience in Clinical Research, Drug Development, and clinical practice, after getting education from top medical schools of India. Atul joined Navitas in February 2021, and prior to that he has worked with leading organizations like Ranbaxy, Panacea Biotec, Max Neeman International and Apcer Life Sciences. Atul has rich leadership experience in providing end to end scientific guidance in drug development (Phase 1-IV) across multiple therapeutic area portfolios, in diverse regulatory environments including FDA, EMA, MHRA, ANVISA and DCGI. Atul has been extensively involved in defending clinical strategy proposals with respect to scientific rationale, timelines and budget with senior executives. He has worked as Global Medical Lead (USA, Europe and Asia Pacific) in more than 50 studies across the continents for both drugs and devices. Atul has been involved extensively in developing complex innovative trial designs for complex protocols reducing the huge costs and time associated with standard clinical randomized controlled trials.
Apart from being a medical lead, atul has multifaceted experience in diverse clinical research domains including medical writing (Protocol, IB, CSR, eCTD etc), medico-regulatory (IND, NDA, BLA), drug safety and operations. Atul has been actively involved in multiple DSMBs and SRCs. He has been involved in negotiating clinical plans with FDA during pre-IND and type C meetings. He has been the part of successful marketing authorization approval of breakthrough therapies including PD-1 inhibitors, V2 antagonist, multiple biosimilars, vaccines and several repurposed therapies (for MDD, narcolepsy, psoriasis)
Harit Nandani has 12+ years of experience in clinical trials data and technology leadership for both diagnostics and therapeutic trials. He specializes in clinical trial data management and analysis, configuring systems for population-scale studies, and using analytics tools to monitor projects. Currently, he is the Director of Clinical Data Management at GRAIL, overseeing data and systems for trials in the UK and US supporting early cancer detection diagnostics development. He has worked on projects enrolling over 300,000 participants, leading to the development of the Galleri test, which has detected over 50 types of cancer and has been named one of TIME Magazine’s best inventions and The Atlantic’s 10 most promising breakthroughs of 2022. Prior to GRAIL, Harit led late-stage pivotal trials in Oncology at Gilead Sciences and worked in various clinical research roles at a CRO and a small biopharmaceutical development company.
Joe has worked in the Life Science industries for sixteen years, with eight of those years spent working directly with patient-facing technologies. During Joe’s time working with eClinical technologies, he has worked with a range of trial sponsors in both the public and private sectors, across Europe and the US, assisting in the deployment of a range of technologies to help optimise their clinical studies, including; patient registries, ePRO/eCOA, eConsent and safety solutions.
Following his degrees in Biomedical Science and Pharmaceuticals, Adam has worked within the pharma industry for 10 years bringing with him a wealth of experience in Regulatory Affairs, RWE and Digital Health Technologies. By strategizing with Sponsors, he has helped bring successful clinical trials to fruition, maximizing use of patient facing technologies including eCOA, eConsent, Wearables and Telehealth. Adam has a keen interest in Patient Reported Outcomes and endpoint development for evidence-based decision making, utilizing subjective and objective evidence to provide maximum value for all stakeholders in the value chain.
As Vice President, FSP Commercial and Operational Strategy, Neil Berger is an operational and commercial strategist for clinical development outsourcing solutions at Parexel. Bringing 20 years of commercial and research operations experience, he is a recognized expert in holistic and cross-functional approaches to talent development – integrating acquisition, development and retention to meet long-term portfolio needs for biopharmaceutical sponsors.
Prior to joining Parexel in 2015 as a commercial account leader, Neil held a range of positions of increasing responsibility in project management and client services for Pharma Medica Research, a contract research organization based in Canada.
Neil earned a master of business administration degree from Schulich School of Business, and holds a master’s and bachelor’s degree in science from McGill University.
Henrik Schou is the Global Head Evidence Generation at CSL-VIFOR PHARMA. Henrik has been in the industry for more than 20 years in different geographies and roles, where evidence generation has been an essential piece. Henrik has cradle to grave experience in all aspects of evidence generation, and use to satisfy regulatory, reimbursement and medical affairs objectives.
Henrik is a Mathematician from University of Aarhus in Denmark, Postgraduate in Health Economics from University of York in the UK. A diploma in Pharmaceutical Medicine from Kings College in London and a Management Diploma from Harvard Business School.
As Vice President of Sales, EMEA & APAC, for Sweegen, Damian is a driven, innovative and highly successful “hands on” commercial leader. With 25 years of commercial experience within the flavor & fragrance and specialty ingredient markets, he is highly committed to delivering value through business growth and inter-departmental efficiency. Damian is skilled at the development and execution of local, regional, and global strategies across matrix organizations and has a proven track record as a multinational team builder, delivering unrivalled sales success in highly competitive global flavors and fragrance and natural sweetener markets. He is based in Reading, England.
